文献速递中毒与环境急症消化、代谢与肾脏急症

阿片类替代治疗期间及之后的全因与过量死亡风险:队列研究的系统评价与荟萃分析

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
PubMed 文献 · BMJ · 2017-04-26
一句话结论美沙酮和丁丙诺啡替代治疗期间全因及过量死亡风险显著低于脱离治疗期间,美沙酮诱导期及两种药物停药后即刻为死亡风险高危窗口。

该系统评价与荟萃分析纳入19项前瞻或回顾性队列,共122885例美沙酮治疗者(随访1.3–13.9年)和15831例丁丙诺啡治疗者(随访1.1–4.5年)。汇总显示美沙酮治疗期间全因死亡率11.3/1000人年,脱离治疗期间36.1/1000人年(未调整脱离/治疗率比3.20,95%CI 2.65–3.86);丁丙诺啡分别为4.3和9.5/1000人年(率比2.20,95%CI 1.34–3.61)。过量死亡率变化相似,美沙酮治疗期间2.6 vs 脱离期间12.7/1000人年(率比4.80,95%CI 2.90–7.96),丁丙诺啡1.4 vs 4.6/1000人年。作者认为保留治疗与死亡风险大幅降低相关,美沙酮诱导期和两种药物停药后即刻为风险增高期,需公共卫生与临床策略应对。

要点

  • 美沙酮治疗期间全因死亡率11.3/1000人年,脱离治疗期间36.1/1000人年,脱离/治疗率比3.20(95%CI 2.65–3.86)。
  • 丁丙诺啡治疗期间全因死亡率4.3/1000人年,脱离治疗期间9.5/1000人年,脱离/治疗率比2.20(95%CI 1.34–3.61)。
  • 美沙酮治疗期间过量死亡率2.6/1000人年,脱离期间12.7/1000人年,率比4.80(95%CI 2.90–7.96);丁丙诺啡分别为1.4和4.6/1000人年。
  • 美沙酮治疗前四周全因死亡率急剧下降,脱离治疗后两周逐渐下降;丁丙诺啡诱导期及治疗全程全因死亡率保持稳定。
  • 作者认为美沙酮诱导期和两种药物停药后即刻为死亡风险特别增高期,需公共卫生与临床策略应对。

适用人群与场景

  • 阿片类药物依赖者,纳入前瞻性或回顾性队列研究,报告美沙酮或丁丙诺啡替代治疗期间及脱离治疗期间随访的全因或过量死亡。
  • 美沙酮队列共122885人,随访1.3–13.9年;丁丙诺啡队列共15831人,随访1.1–4.5年。

红旗征与不能漏的情况

  • 美沙酮治疗诱导期(前四周)全因死亡率处于高危窗口。
  • 脱离美沙酮或丁丙诺啡治疗后的即刻阶段死亡风险增高。

研究设计与关键结果

  • 系统评价与荟萃分析纳入19项合格队列(前瞻或回顾性),采用多变量随机效应荟萃分析联合合并治疗期间与脱离治疗期间的死亡率。
  • 美沙酮全因死亡率:治疗期间11.3/1000人年 vs 脱离期间36.1/1000人年,未调整脱离/治疗率比3.20(95%CI 2.65–3.86)。
  • 丁丙诺啡全因死亡率:治疗期间4.3/1000人年 vs 脱离期间9.5/1000人年,未调整脱离/治疗率比2.20(95%CI 1.34–3.61)。
  • 美沙酮过量死亡率:治疗期间2.6/1000人年 vs 脱离期间12.7/1000人年,未调整脱离/治疗率比4.80(95%CI 2.90–7.96);丁丙诺啡过量死亡率:治疗期间1.4/1000人年 vs 脱离期间4.6/1000人年。
  • 趋势分析:美沙酮治疗前四周全因死亡率急剧下降,脱离治疗后两周逐渐下降;丁丙诺啡诱导期及治疗剩余时间全因死亡率保持稳定;过量死亡率变化模式相似。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入19项前瞻或回顾性队列研究,采用多变量随机效应荟萃分析。
  • 作者指出进一步研究必须开展,以在比较不同阿片类替代治疗之间以及各治疗期间与脱离治疗期间的死亡风险时,恰当处理潜在混杂与选择偏倚。

对床旁实践的改变

  • 作者认为保留美沙酮和丁丙诺啡治疗与阿片依赖者全因及过量死亡风险大幅降低相关。
  • 作者认为美沙酮诱导期和两种药物停药后即刻为死亡风险特别增高期,需公共卫生与临床策略应对以降低该风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objective To compare the risk for all cause and overdose mortality in people with opioid dependence during and after substitution treatment with methadone or buprenorphine and to characterise trends in risk of mortality after initiation and cessation of treatment.Design Systematic review and meta-analysis.Data sources Medline, Embase, PsycINFO, and LILACS to September 2016.Study selection Prospective or retrospective cohort studies in people with opioid dependence that reported deaths from all causes or overdose during follow-up periods in and out of opioid substitution treatment with methadone or buprenorphine.Data extraction and synthesis Two independent reviewers performed data extraction and assessed study quality. Mortality rates in and out of treatment were jointly combined across methadone or buprenorphine cohorts by using multivariate random effects meta-analysis.Results There were 19 eligible cohorts, following 122 885 people treated with methadone over 1.3-13.9 years and 15 831 people treated with buprenorphine over 1.1-4.5 years. Pooled all cause mortality rates were 11.3 and 36.1 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 3.20, 95% confidence interval 2.65 to 3.86) and reduced to 4.3 and 9.5 in and out of buprenorphine treatment (2.20, 1.34 to 3.61). In pooled trend analysis, all cause mortality dropped sharply over the first four weeks of methadone treatment and decreased gradually two weeks after leaving treatment. All cause mortality remained stable during induction and remaining time on buprenorphine treatment. Overdose mortality evolved similarly, with pooled overdose mortality rates of 2.6 and 12.7 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 4.80, 2.90 to 7.96) and 1.4 and 4.6 in and out of buprenorphine treatment.Conclusions Retention in methadone and buprenorphine treatment is associated with substantial reductions in the risk for all cause and overdose mortality in people dependent on opioids. The induction phase onto methadone treatment and the time immediately after leaving treatment with both drugs are periods of particularly increased mortality risk, which should be dealt with by both public health and clinical strategies to mitigate such risk. These findings are potentially important, but further research must be conducted to properly account for potential confounding and selection bias in comparisons of mortality risk between opioid substitution treatments, as well as throughout periods in and out of each treatment.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017. PMID: 28446428. doi:10.1136/bmj.j1550

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。